LoginCreate an account

  Username: Password:
 
Home mySSlife Health Merck, Portola in $420M deal for anticlotting drug

Merck, Portola in $420M deal for anticlotting drug

E-mail Print PDF
User Rating: / 0
PoorBest 

WHITEHOUSE STATION, N.J. (AP) — Merck & Co. and Portola Pharmaceuticals Inc. say they have an exclusive deal to develop and market an experimental drug to prevent strokes in people with a dangerous irregular heart rhythm.

Merck, the world's eighth-biggest drugmaker, will pay Portola $50 million initially to license the drug, called betrixaban.

The drug prevents blood clots by blocking a clotting substance called Factor Xa. The pill would be taken daily by people with atrial fibrillation, a sometimes deadly abnormal heart rhythm.

Betrixaban is currently in mid-stage testing. Merck would cover costs of future testing. If that goes well and the drug is approved for sale, Portola could earn up to $420 million in payments from Merck, plus sales royalties.

 

Copyright 2009 The Associated Press.

 

 
Sanjay Gupta MD (video)
Finally, straight answers about your health.
  • I want candy!
    For Halloween, CNN's Dr. Sanjay Gupta and CNN Eatocracy's Kat Kinsman talk candy nostalgia and the worst candy available.
  • Brother doctors freed from Iran, reunite
    Sanjay Gupta interviews two brothers, both doctors, who were imprisoned in Iran while treating HIV/AIDS patients.
  • The next killer virus
    CNN's Dr. Sanjay Gupta talks with virologist Nathan Wolfe about finding infectious diseases before they spread too far.
FOXNews.com
FOX News Network - We Report. You Decide.

Search...

WebSite

mySSnews Login



User Menu